Search

Displaying results 4051 - 4060 of 10000 in total
  1. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    The Company determined that the program was not meeting their expected primary and exploratory objectives. … It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

  2. Drug

    Clorazepic acid

    go.drugbank.com/drugs/DB00628
    ApprovedIllicit

    [A957,L44788] Following administration, clorazepate is rapidly converted to nordiazepam (N-desmethyldiazepam), its active metabolite, before entering systemic circulation. … [A256683,T883] The concomitant use of clorazepate and opioids may result in profound sedation, respiratory depression, coma, and death.

  3. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone … Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment

  4. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.

  5. Drug

    Omapatrilat

    go.drugbank.com/drugs/DB00886
    Experimental

    This drug from BMS was not approved by the FDA due to angioedema safety concerns.

  6. Drug

    CX-051869

    go.drugbank.com/drugs/DB31656
    Approved

    CX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1. It is the active ingredient of the 2025-2026 formulation of Moderna's Spikevax vaccine.

  7. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.

  8. Indication

    Skin Ulcer

    go.drugbank.com/conditions/DBCOND0029261
    Drugs: Bacitracin · Becaplermin · Bendazac · Centella asiatica · Neomycin · Sulfathiazole
    Synonyms: Skin ulcer NOS, Non-pressure chronic ulcer of skin, not elsewhere classified
  9. Drug

    Cretostimogene grenadenorepvec

    go.drugbank.com/drugs/DB05148
    Investigational

    CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF.

  10. Target

    Aclacinomycin 10-hydroxylase RdmB

    go.drugbank.com/bio_entities/BE0002526
    TargetStreptomyces purpurascens

    In vivo and in vitro, RdmB catalyzes the removal of the carboxylic group from the C-10 position of 15-demethoxyaclacinomycin T coupled to hydroxylation at the same C-10 position. … It could also catalyze the removal of the carboxylic group at the C-10 position of 15-demethoxy-epsilon-rhodomycin coupled to hydroxylation at the same C-10 position to yield rhodomycin B.

    Synonyms: SAM-dependent methyltransferase RdmB